Salinomycin
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Salinomycin
- DrugBank Accession Number
- DB11544
- Background
Not Available
- Type
- Small Molecule
- Groups
- Vet approved
- Structure
- Weight
- Average: 751.011
Monoisotopic: 750.491813074 - Chemical Formula
- C42H70O11
- Synonyms
- Procoxacin
- Salinomycin
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcenocoumarol The risk or severity of bleeding can be increased when Salinomycin is combined with Acenocoumarol. Ambroxol The risk or severity of methemoglobinemia can be increased when Salinomycin is combined with Ambroxol. Articaine The risk or severity of methemoglobinemia can be increased when Salinomycin is combined with Articaine. BCG vaccine The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Salinomycin. Benzocaine The risk or severity of methemoglobinemia can be increased when Salinomycin is combined with Benzocaine. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Salinomycin sodium 92UOD3BMEK 55721-31-8 YPZYGIQXBGHDBH-UZHRAPRISA-M
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as diterpene glycosides. These are diterpenoids in which an isoprene unit is glycosylated.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Prenol lipids
- Sub Class
- Terpene glycosides
- Direct Parent
- Diterpene glycosides
- Alternative Parents
- Diterpenoids / Fatty alcohols / Branched fatty acids / Heterocyclic fatty acids / Hydroxy fatty acids / Ketals / Beta-hydroxy ketones / Oxanes / Pyrans / Tertiary alcohols show 8 more
- Substituents
- Acetal / Alcohol / Aliphatic heteropolycyclic compound / Beta-hydroxy ketone / Branched fatty acid / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Dialkyl ether / Diterpene glycoside show 20 more
- Molecular Framework
- Aliphatic heteropolycyclic compounds
- External Descriptors
- diterpene glycoside (CHEBI:80025)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 62UXS86T64
- CAS number
- 53003-10-4
- InChI Key
- KQXDHUJYNAXLNZ-XQSDOZFQSA-N
- InChI
- InChI=1S/C42H70O11/c1-11-29(38(46)47)31-15-14-23(4)36(50-31)27(8)34(44)26(7)35(45)30(12-2)37-24(5)22-25(6)41(51-37)19-16-32(43)42(53-41)21-20-39(10,52-42)33-17-18-40(48,13-3)28(9)49-33/h16,19,23-34,36-37,43-44,48H,11-15,17-18,20-22H2,1-10H3,(H,46,47)/t23-,24-,25+,26-,27-,28-,29+,30-,31+,32+,33+,34+,36+,37-,39-,40+,41-,42-/m0/s1
- IUPAC Name
- (2R)-2-[(2R,5S,6R)-6-[(2S,3S,4S,6R)-6-[(2S,5S,7R,9S,10S,12R,15R)-2-[(2R,5R,6S)-5-ethyl-5-hydroxy-6-methyloxan-2-yl]-15-hydroxy-2,10,12-trimethyl-1,6,8-trioxadispiro[4.1.5⁷.3⁵]pentadec-13-en-9-yl]-3-hydroxy-4-methyl-5-oxooctan-2-yl]-5-methyloxan-2-yl]butanoic acid
- SMILES
- [H][C@@](C)(C(=O)[C@]([H])(CC)[C@@]1([H])O[C@@]2(O[C@@]3(CC[C@](C)(O3)[C@@]3([H])CC[C@](O)(CC)[C@]([H])(C)O3)[C@]([H])(O)C=C2)[C@]([H])(C)C[C@]1([H])C)[C@@]([H])(O)[C@]([H])(C)[C@]1([H])O[C@]([H])(CC[C@]1([H])C)[C@@]([H])(CC)C(O)=O
References
- General References
- Potter LM, Blake JP, Blair ME, Bliss BA, Denbow DM: Salinomycin toxicity in turkeys. Poult Sci. 1986 Oct;65(10):1955-9. [Article]
- Horrox NE: Salinomycin poisoning in turkeys. Vet Rec. 1984 Jan 14;114(2):52. [Article]
- Aleman M, Magdesian KG, Peterson TS, Galey FD: Salinomycin toxicosis in horses. J Am Vet Med Assoc. 2007 Jun 15;230(12):1822-6. [Article]
- Rollinson J, Taylor FG, Chesney J: Salinomycin poisoning in horses. Vet Rec. 1987 Aug 8;121(6):126-8. [Article]
- Pott JM: Salinomycin toxicity in pigs. Vet Rec. 1990 Dec 1;127(22):554. [Article]
- Vertesy L, Heil K, Fehlhaber HW, Ziegler W: Microbial decomposition of salinomycin. J Antibiot (Tokyo). 1987 Mar;40(3):388-90. [Article]
- Stuart JC: Salinomycin poisoning in turkeys. Vet Rec. 1983 Dec 17;113(25):597. [Article]
- Kavanagh NT, Sparrow DS: Salinomycin toxicity in pigs. Vet Rec. 1990 Nov 17;127(20):507. [Article]
- Harries N: Alberta. Salinomycin toxicity in turkeys. Can Vet J. 1991 Feb;32(2):117. [Article]
- Huyben MW, Sol J, Counotte GH, Roumen MP, Borst GH: Salinomycin poisoning in veal calves. Vet Rec. 2001 Aug 11;149(6):183-4. [Article]
- External Links
- KEGG Drug
- D08502
- KEGG Compound
- C15690
- ChemSpider
- 2342058
- 1311566
- ChEBI
- 80025
- ChEMBL
- CHEMBL1208572
- ZINC
- ZINC000085540254
- Wikipedia
- Salinomycin
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00297 mg/mL ALOGPS logP 4.48 ALOGPS logP 7.51 Chemaxon logS -5.4 ALOGPS pKa (Strongest Acidic) 4.45 Chemaxon pKa (Strongest Basic) -3 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 11 Chemaxon Hydrogen Donor Count 4 Chemaxon Polar Surface Area 161.21 Å2 Chemaxon Rotatable Bond Count 12 Chemaxon Refractivity 200.07 m3·mol-1 Chemaxon Polarizability 81.82 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 239.96632 predictedDeepCCS 1.0 (2019) [M+H]+ 241.68082 predictedDeepCCS 1.0 (2019) [M+Na]+ 247.83766 predictedDeepCCS 1.0 (2019)
Transporters
1. DetailsP-glycoprotein 1
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
- Gene Name
- ABCB1
- Uniprot ID
- P08183
- Uniprot Name
- Multidrug resistance protein 1
- Molecular Weight
- 141477.255 Da
References
- Riccioni R, Dupuis ML, Bernabei M, Petrucci E, Pasquini L, Mariani G, Cianfriglia M, Testa U: The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor. Blood Cells Mol Dis. 2010 Jun 15;45(1):86-92. doi: 10.1016/j.bcmd.2010.03.008. Epub 2010 May 4. [Article]
- Kim WK, Kim JH, Yoon K, Kim S, Ro J, Kang HS, Yoon S: Salinomycin, a p-glycoprotein inhibitor, sensitizes radiation-treated cancer cells by increasing DNA damage and inducing G2 arrest. Invest New Drugs. 2012 Aug;30(4):1311-8. doi: 10.1007/s10637-011-9685-6. Epub 2011 May 15. [Article]
Drug created at February 26, 2016 17:41 / Updated at January 14, 2023 19:02